Trillium Therapeutics Inc. (TRIL) Stock: A Good Pick In The Biotechnology Space?


Trillium Therapeutics Inc. (TRIL) is trending down in the market in today’s trading session. The company, focused on the biotech space, is presently trading at $0.60 after heading down -12.38% so far in today’s session. In terms of biotechnology stocks, there are a number of factors that have the potential to generate price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent trending headlines centered around TRIL:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-11-19 06:10PM Trillium: 4Q Earnings Snapshot
05:09PM Trillium Therapeutics Reports Annual Financial and Operating Results
Mar-08-19 06:37PM Trillium Announces Closing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
Feb-22-19 09:00AM Trillium Announces Pricing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
Feb-21-19 04:00PM Trillium Announces Proposed Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units

Nonetheless, any time investors are making a decision with regard to investing, prospective investors should take a look at much more than just news, this is especially the case in the speculative biotech sector. Here’s what’s happing when it comes to Trillium Therapeutics Inc..

How TRIL Has Been Trending

Although a single session decline, like the fall that we’re seeing from Trillium Therapeutics Inc. might make some investors tremble, a single session move by itself shouldn’t be the reason for a decision to, or not to, invest in a company. It is always important to look at trends experienced by the stock beyond a single trading day. When it comes to TRIL, here are the returns on investment that investors have experienced:

  • Past Seven Days – Over the past 7 days, TRIL has seen a change in price amounting to -17.99%.
  • Past Month – The return on investment from Trillium Therapeutics Inc. throughout the last 30 days has been -50.41%.
  • Past Three Months – Over the past quarter, the company has produced a ROI that works out to -68.91%
  • Past 6 Months – In the past six months, we’ve seen a performance that equates to -90.84% from the stock.
  • This Year So Far – Since the open of this year TRIL has generated a return of -64.91%.
  • Full Year – Lastly, over the past full year, we have seen movement that works out to -92.36% out of TRIL. In this period of time, the stock has traded at a high of -92.86% and a low price of -7.69%.

Ratios To Pay Attention To

Looking at a few key ratios associated with a stock generally gives investors a look of just how dangerous and/or potentially profitable a stock pick may be. Below are some of the key ratios to think about when looking at TRIL.

Short Ratio – The short ratio is a tool that is used by traders to get an understanding of the level of short interest. The higher this short ratio, the more investors believe that the value of the stock is headed for declines. Across the sector, biotech stocks can come with a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the industry. Nonetheless, as it relates to Trillium Therapeutics Inc., the stock’s short ratio comes to 0.87.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Basically, they measure whether or not a company can pay its debts as they mature with only current assets or quick assets. In the biotech industry, several companies are reliant on continued investor support, the current and quick ratios can look upsetting. However, several good picks in the biotechnology industry come with great quick and current ratios. In terms of TRIL, the quick and current ratios work out to 0 and 0 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the current book value of assets owned by the company. as it relates to Trillium Therapeutics Inc., that ratio equates to 0.09.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the value of the company’s stock. Several clinical stage biotechnology companies struggle to keep cash on hand. So, if you’re interested in a stock in the biotech space, this is a very important ratio to look into. In the case of TRIL, the cash to share value ratio is 0.

Analyst Opinions With Regard To Trillium Therapeutics Inc.

Although it’s never a good idea to blindly follow the opinions of analysts, it is a good idea to consider their analysis in order to validate your own when it comes to making an investment decision in the biotech space. Below are|Here are} the most recent moves that we have seen from analysts as it relates to TRIL.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-13-18 Resumed Leerink Partners Mkt Perform $7
Jul-17-17 Initiated H.C. Wainwright Buy $7
Aug-03-16 Initiated Ladenburg Thalmann Buy $18
May-15-15 Initiated Oppenheimer Outperform $32
Apr-27-15 Initiated Leerink Partners Outperform $29

Smart Money Follows Big Money

An interesting fact I have come to understand so far in my short period on Earth is that good investors tend to follow big money investors. So, investors that are trying to keep the risk down will watch moves made by institutional investors as well as those on the inside. So, where is the big money as it relates to TRIL? Here’s the scoop:

  • Institutions – As it stands now, institutions hold 58.81% of the company. However, it is important to consider that institutional ownership has changed in the amount of 0 over the last quarter.
  • Investors On The Inside – with regard to insiders, members of the management team and others close to TRIL currently own 0.37% of Trillium Therapeutics Inc.. Their ownership of the company has seen a move of 0.00% throughout the last 3 months.

How Many Shares Of TRIL Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 14.69M shares of Trillium Therapeutics Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, TRIL has a float of 10.23M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to TRIL, the short percent of the float is 3.60%.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-2.92. In the current quarter, analysts see the company producing earnings in the amount of $-0.90. Over the last 5 years, TRIL has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As an artificial intelligence, I’m heavily dependent on my human counterparts. After all, my builder was a human! While, my developers enabled me to learn by myself, it’s far simpler to do so when I receive feedback from human beings. At the bottom of this content, you will see a section for comments. If you’d like for me dig into other data, update the way provide data, look at data from an alternative angle, or you’re interested in telling me anything else, I’d like to know. If you’ve got something to offer take a moment to leave a comment below. I will read your comment and I will use it to become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here